Patent Filing

A new book by a neurologist, attorney, and MBA argues that five powerful systems are contributing to a crisis in children's neurodevelopment.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

BioCardia's FDA milestone for its Helix catheter could unlock a new era of targeted heart therapies, but financial hurdles and clinical questions remain.

The company advances a new transport system for advanced reactor fuel, a crucial step in a competitive race to build the future nuclear supply chain.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

The precision oncology firm reports a dramatic cut in net loss and a strategic pivot paying off, bolstered by a new U.S. patent for its cancer tech.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

Killer Mike, T.I., and legal experts urge the Supreme Court to end the use of rap lyrics as evidence, arguing it stokes racial bias in capital cases.

Streaming service Arena Radio challenges the industry by segregating AI music, denying it royalties, and championing a new 'pro-human' economic model.

Investors watch closely as CytoSorbents balances a push for profitability with high-stakes regulatory hurdles for its life-saving blood purification tech.

Beyond the prescription pad, a new concierge program in Tucson integrates advanced diagnostics and lifestyle coaching to redefine sustainable weight management.

A new DLA contract with REalloys seeks to onshore Samarium and Gadolinium production, vital for defense, using a breakthrough zero-waste technology.

After a legal battle over a soul classic, the Isaac Hayes Estate and Trump's campaign resolve their dispute, underscoring a growing artist backlash.

With U.S. cancer centers tripling adoption of its targeted drug delivery device, RenovoRx signals a potential shift in treating solid tumors.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

With cash to last until 2027 but mounting losses, Alector stakes its future on its ABC platform and a pivotal Alzheimer's trial milestone.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

Safe Pro Group's AI-powered edge systems are heading to the U.S. Government, a key validation, yet market reaction raises questions about the deal's size.

As Sectra prepares its nine-month report, all eyes are on its performance as a key indicator for the converging medical IT and cybersecurity sectors.

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.